Zev A. Wainberg, MD, on Future Research Efforts for Patients With Advanced Gastric Cancer

Video

Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Gastrointestinal (GI) Cancer Symposium, Zev A. Wainberg, MD, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the GI Oncology Program at UCLA, highlighted future research efforts in the advanced gastric cancer space. Some of these pieces of research include large, randomized studies that will aim to further explore the role of pembrolizumab (Keytruda) within this patient population.

Transcript:

Obviously, the landscape has changed. We have frontline data with nivolumab [Opdivo], which has established it as the standard in [patients with a] CPS greater than 5 with chemotherapy. We have the [phase 3] KEYNOTE-811 study [NCT03615326], which established pembrolizumab plus chemotherapy plus trastuzumab [Herceptin] upfront in HER2-positive disease. There are 2 large, randomized phase 3 trials which will clarify the role of pembrolizumab a little bit further. There's something called the [phase 3 KEYNOTE-859] study [NCT03675737], which is a large, global study of pembrolizumab upfront with chemotherapy to look at whether there are any subsets in which you get benefit with chemotherapy plus pembrolizumab over chemotherapy alone. That study is still waiting to read out in the next year or so.

Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content